TMAO-Induced Aging Model in Midbrain Organoids for Parkinson's Disease Modeling
Source Lee et al., 2022 · Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, South Korea · 10.3389/fnagi.2022.925227
Abstract
This protocol generates midbrain organoids from human pluripotent stem cells and treats them with trimethylamine N-oxide (TMAO) to induce aging-associated phenotypes. The TMAO-treated midbrain organoids exhibit increased cellular senescence, epigenetic alterations, loss of dopaminergic neurons, astrocyte activation, and pathological protein phosphorylation (α-synuclein and Tau), providing an in vitro model for studying brain aging and Parkinson's disease pathogenesis without genetic modification.
Protocol overview
14 steps across 5 phases
- 1 Culture pluripotent stem cells in TeSR-E8 medium
- 2 Passage cells using ReLeSR
- 1 Dissociate cells to single-cell suspension
- 2 Culture in EBM medium (Day 0–1)
- 3 Switch to BGM medium (Day 1–2)
- 1 Add mesencephalon patterning factors to BGM (Day 2)
- 2 Embed organoids in growth factor-reduced matrigel
- 3 Transfer to ultralow attachment 6-well plate and culture on orbital shaker (Day 9)
- 1 Culture in BMM medium with daily medium changes
- 2 Begin TMAO treatment at 4 weeks of maturation (4WM)
- 3 Maintain organoids until endpoint (30WM total maturation)
- 1 Harvest organoids for RNA extraction
- 2 Prepare organoids for immunostaining
- 3 Prepare conditioned media for dopamine and biochemical assays
Full SOP
Create a free account to access this protocol
Join OrganMatch to unlock step-by-step procedures, reagent concentrations, QC checklists, and downloadable batch record templates.
Create free accountAlready registered? Log in
Attribution
This SOP was authored by Organthis based on the published method in Lee et al., 2022. The originating laboratory holds no rights in this SOP and has not endorsed it unless marked Verified.
This wording is awaiting legal review.
Something wrong with this entry? Report an issue with this protocol